NONOF - Eli Lilly takes early lead in weight loss drug race BMO says
2023-12-29 15:06:27 ET
More on Eli Lilly, Novo Nordisk, etc.
- Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade)
- Eli Lilly: Long Path To A Trillion
- Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
- Key debate themes for the industries in 2024 - MS
- FDA’s new drug approvals for 2023 rise 51% from last year
For further details see:
Eli Lilly takes early lead in weight loss drug race, BMO says